Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy

被引:125
|
作者
Rapoport, Bernardo L. [1 ,2 ]
Anderson, Ronald [1 ,3 ]
机构
[1] Univ Pretoria, Dept Immunol, Fac Hlth Sci, ZA-0001 Pretoria, South Africa
[2] Med Oncol Ctr Rosebank, ZA-2196 Johannesburg, South Africa
[3] Univ Pretoria, Inst Cellular & Mol Med, Fac Hlth Sci, ZA-0001 Pretoria, South Africa
来源
关键词
calreticulin; damage-associated molecular patterns (DAMPs); dendritic cells; high mobility group box1; immunogenic cell death; immune checkpoint inhibitors; monoclonal antibodies; type I interferons; ANTITUMOR IMMUNITY; DNA-DAMAGE; T-CELLS; CALRETICULIN EXPOSURE; CROSS-PRESENTATION; DENDRITIC CELLS; LIGAND; TUMOR; INFLAMMATION; MECHANISMS;
D O I
10.3390/ijms20040959
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunogenic cell death (ICD), which is triggered by exposure of tumor cells to a limited range of anticancer drugs, radiotherapy, and photodynamic therapy, represents a recent innovation in the revitalized and burgeoning field of oncoimmunnotherapy. ICD results in the cellular redistribution and extracellular release of damage-associated molecular patterns (DAMPs), which have the potential to activate and restore tumor-targeted immune responses. Although a convincing body of evidence exists with respect to the antitumor efficacy of ICD in various experimental systems, especially murine models of experimental anticancer immunotherapy, evidence for the existence of ICD in the clinical setting is less compelling. Following overviews of hallmark developments, which have sparked the revival of interest in the field of oncoimmunotherapy, types of tumor cell death and the various DAMPs most prominently involved in the activation of antitumor immune responses, the remainder of this review is focused on strategies which may potentiate ICD in the clinical setting. These include identification of tumor- and host-related factors predictive of the efficacy of ICD, the clinical utility of combinatorial immunotherapeutic strategies, novel small molecule inducers of ICD, novel and repurposed small molecule immunostimulants, as well as the critical requirement for validated biomarkers in predicting the efficacy of ICD.
引用
收藏
页数:27
相关论文
共 50 条
  • [31] Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
    Oliver Kepp
    Lorenzo Galluzzi
    Isabelle Martins
    Frederic Schlemmer
    Sandy Adjemian
    Mickael Michaud
    Abdul Qader Sukkurwala
    Laurie Menger
    Laurence Zitvogel
    Guido Kroemer
    Cancer and Metastasis Reviews, 2011, 30 : 61 - 69
  • [32] Advances in Immunogenic Cell Death for Cancer Immunotherapy
    Ding, Dan
    Jiang, Xiqun
    SMALL METHODS, 2023, 7 (05)
  • [33] Molecular characteristics of immunogenic cancer cell death
    Tesniere, A.
    Panaretakis, T.
    Kepp, O.
    Apetoh, L.
    Ghiringhelli, F.
    Zitvogel, L.
    Kroemer, G.
    CELL DEATH AND DIFFERENTIATION, 2008, 15 (01): : 3 - 12
  • [34] Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
    Kepp, Oliver
    Galluzzi, Lorenzo
    Martins, Isabelle
    Schlemmer, Frederic
    Adjemian, Sandy
    Michaud, Mickael
    Sukkurwala, Abdul Qader
    Menger, Laurie
    Zitvogel, Laurence
    Kroemer, Guido
    CANCER AND METASTASIS REVIEWS, 2011, 30 (01) : 61 - 69
  • [35] Molecular characteristics of immunogenic cancer cell death
    A Tesniere
    T Panaretakis
    O Kepp
    L Apetoh
    F Ghiringhelli
    L Zitvogel
    G Kroemer
    Cell Death & Differentiation, 2008, 15 : 3 - 12
  • [36] Immunogenic cell death and DAMPs in cancer therapy
    Krysko, Dmitri V.
    Garg, Abhishek D.
    Kaczmarek, Agnieszka
    Krysko, Olga
    Agostinis, Patrizia
    Vandenabeele, Peter
    NATURE REVIEWS CANCER, 2012, 12 (12) : 860 - 875
  • [37] Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
    Pol, Jonathan
    Vacchelli, Erika
    Aranda, Fernando
    Castoldi, Francesca
    Eggermont, Alexander
    Cremer, Isabelle
    Sautes-Fridman, Catherine
    Fucikova, Jitka
    Galon, Jerome
    Spisek, Radek
    Tartour, Eric
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2015, 4 (04):
  • [38] Immunogenic cell death in cancer and infectious disease
    Lorenzo Galluzzi
    Aitziber Buqué
    Oliver Kepp
    Laurence Zitvogel
    Guido Kroemer
    Nature Reviews Immunology, 2017, 17 : 97 - 111
  • [39] Immunogenic cell death and DAMPs in cancer therapy
    Dmitri V. Krysko
    Abhishek D. Garg
    Agnieszka Kaczmarek
    Olga Krysko
    Patrizia Agostinis
    Peter Vandenabeele
    Nature Reviews Cancer, 2012, 12 : 860 - 875
  • [40] Reactive species in immunogenic cancer cell death
    Bekeschus, Sander
    Lilllig, Christopher-Horst
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 120 : S56 - S56